Delcath Systems (DCTH)
Drug: Percutaneous Hepatic Perfusion
Abstract No. LBA8512Indication: Liver metastases from melanoma Clinical Trial: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. Presentation Time: Saturday, June 5. Oral session. Notes: Investors will get the first detailed look at data from the positive phase III study announced last week.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts